The Blushwood Berry, native to the rainforests of Far North Queensland, Australia, has captured global interest for its unique compound, EBC-46. This naturally occurring extract has been studied in preclinical and veterinary research for its potential effects on tumors and immune response. While some studies report promising outcomes, human research is limited, and EBC-46 is not approved by the FDA to diagnose, treat, cure, or prevent disease.

Beyond ongoing scientific investigation, Blushwood Berry is also valued for its naturally occurring bioactive compounds, which may contribute to antioxidant and wellness support. Researchers continue to explore how this plant-derived compound works, including its potential influence on immune activity and cellular health.

At Aussie Pure, our mission is to make Blushwood Berry available in its most natural and pure form. While much of the current research focuses on creating synthetic versions of EBC-46 for pharmaceutical use, we remain dedicated to offering carefully sourced, lab-tested Blushwood Berry products you can trust.

This page brings together trusted resources, articles, and scientific studies to help you stay informed about the latest research and potential applications of Blushwood Berry (EBC-46).

 

 

Synthesis and preclinical evaluation of tigilanol tiglate analogs as latency-reversing agents for the eradication of HIV
This article highlights research showing that tigilanol tiglate (EBC-46) and its analogs can reactivate dormant HIV, a key step toward potential cure strategies. The study demonstrates EBC-46’s ability to modulate protein kinase C pathways and opens the door to broader applications beyond cancer treatment. 

Read more here.

QBiotics wins FDA orphan status for rainforest-derived cancer drug
This article stipulates that even though the designation is for soft tissue sarcoma, tigilanol tiglate is in clinical trials for multiple cancer types.
Read more here.

From the Bush to the Brain: Preclinical Stages of Ethnobotanical Anti-Inflammatory and Neuroprotective Drug Discovery—An Australian Example
This article discusses EBC-46, a compound derived from the seeds of the blushwood tree (Hylandia dockrillii), and its potential applications in drug discovery and cancer treatment.
Read more here.

Breakthrough in Production of Cancer-Treating Drug
This report details the synthetic production of EBC-46 and its mechanism of action in treating tumors, highlighting its effectiveness in animal models and its potential for human clinical trials.
Read more here.

Cancer Tumors Destroyed by Berry Found in Queensland Rainforest
This study outlines the effectiveness of EBC-46 in destroying cancerous tumors in animal models, providing insights into its rapid action and potential as a treatment option.
Read more here.

Rare Australian Berries Might Contain Possible Cancer Treatment
This article discusses the discovery of EBC-46 and its promising results in preclinical trials for treating various types of cancer in animals, emphasizing its unique properties derived from the blushwood berry.
Read more here.

Scientists Discover Cancer-Fighting Berry on Tree that Only Grows in Far North Queensland
This piece reports on the rapid tumor-fighting properties of EBC-46 and its successful application in veterinary medicine, with a focus on ongoing research for human applications.
Read more here.